Tectonic Advisors LLC Boosts Stake in Zoetis Inc. (NYSE:ZTS)

Tectonic Advisors LLC raised its holdings in Zoetis Inc. (NYSE:ZTS) by 33.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,509 shares of the company’s stock after acquiring an additional 1,130 shares during the period. Tectonic Advisors LLC’s holdings in Zoetis were worth $735,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Darwin Wealth Management LLC bought a new position in shares of Zoetis in the third quarter worth approximately $31,000. First Personal Financial Services purchased a new position in Zoetis in the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new position in shares of Zoetis in the 3rd quarter worth $33,000. Dunhill Financial LLC raised its position in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares in the last quarter. Finally, Fortitude Family Office LLC raised its position in shares of Zoetis by 1,387.5% during the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after buying an additional 222 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 2.0 %

Shares of NYSE ZTS opened at $175.65 on Thursday. The firm’s fifty day moving average is $169.41 and its 200 day moving average is $179.35. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The company has a market cap of $79.25 billion, a price-to-earnings ratio of 33.02, a PEG ratio of 2.72 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.36 earnings per share. On average, equities research analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.14%. The ex-dividend date of this dividend is Tuesday, January 21st. This is an increase from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s payout ratio is currently 37.59%.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Morgan Stanley reduced their price objective on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. upped their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Stifel Nicolaus decreased their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $215.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.